Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use
The present invention describes a new crystalline form of triethylenetetramine tetrachloride which has improved room temperature stability over known forms and over the dichloride salt. The new crystalline form is characterised by having peaks in an XRPD spectrum at 22.9, 25.4, 25.8, 26.6, 34.6 and 35.3±0.1° 2θ and Raman shifts 943, 1173, 1527 and 1612±5 cm −1 . The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.
1 . A pharmaceutical composition for treating Wilson's disease in a subject in need thereof, wherein the composition comprises a therapeutically effective amount of crystalline triethylenetetramine tetrahydrochloride, wherein at least 50% by weight of the crystalline triethylenetetramine tetrahydrochloride is Form B and no more than 50% by weight of the crystalline triethylenetetramine tetrahydrochloride is Form A, wherein:
Form B has at least one of the following characteristics:
(i) an XRPD pattern having at least two peaks selected from the peaks at 22.9, 25.4, 25.8, 26.6, 34.6 and 35.3±0.1° 2θ; and/or
(ii) a Raman spectrum having at least two peaks selected from the peaks at a Raman shift of 943, 1173, 1527 and 1612±5 cm −1 ; and
Form A has an XRPD pattern having peaks at 25.2 and 35.7±0.1° 2θ, and wherein the therapeutically effective amount is from about 0.001 to 50 mg/kg per body weight of the subject.
2 . The pharmaceutical composition according to claim 1 , wherein Form B has an XRPD pattern having peaks at 25.4, 34.6 and 35.3±0.1° 2θ.
3 . The pharmaceutical composition according to claim 1 , which comprises no more than 40 wt % of the triethylenetetramine tetrahydrochloride Form A having an XRPD pattern having peaks at 25.2 and 35.7±0.1° 2θ.
4 . The pharmaceutical composition according to claim 1 , which comprises no more than 20 wt % of triethylenetetramine tetrahydrochloride Form A having an XRPD pattern having peaks at 25.2 and 35.7±0.1° 2θ.
5 . The pharmaceutical composition according to claim 1 and a pharmaceutically acceptable carrier or diluent.
6 . The pharmaceutical composition according to claim 5 , wherein the pharmaceutical composition is a solid oral dosage form.
7 . The pharmaceutical composition according to claim 6 , wherein the solid oral dosage form comprises a tablet, capsule or powder.
8 . The pharmaceutical composition according to claim 7 , wherein the solid oral dosage form is a tablet.
9 . The pharmaceutical composition according to claim 1 , which comprises no more than 10 wt % triethylenetetramine tetrahydrochloride Form A having an XRPD pattern having peaks at 25.2 and 35.7±0.1° 2θ.
10 . The pharmaceutical composition according to claim 9 , which comprises no more than 5 wt % triethylenetetramine tetrahydrochloride Form A having an XRPD pattern having peaks at 25.2 and 35.7±0.1° 2θ.
11 . The pharmaceutical composition according to claim 1 , wherein the subject is a mammal.
12 . The pharmaceutical composition according to claim 11 , wherein the mammal is a human.
13 . A method of treating Wilson's disease in a subject in need thereof comprising administering to said subject a pharmaceutical composition which comprises a therapeutically effective amount of crystalline triethylenetetramine tetrahydrochloride, wherein at least 50% by weight of the crystalline triethylenetetramine tetrahydrochloride is Form B and no more than 50% by weight of the crystalline triethylenetetramine tetrahydrochloride is Form A, wherein:
Form B has at least one of the following characteristics:
(i) an XRPD pattern having at least two peaks selected from the peaks at 22.9, 25.4, 25.8, 26.6, 34.6 and 35.3±0.1° 2θ; and/or
(ii) a Raman spectrum having at least two peaks selected from the peaks at a Raman shift of 943, 1173, 1527 and 1612±5 cm −1 ; and
Form A has an XRPD pattern having peaks at 25.2 and 35.7±0.1° 2θ, and wherein the therapeutically effective amount is from about 0.001 to 50 mg/kg per body weight of the subject.
14 . The method according to claim 13 , wherein the XRPD pattern has peaks at 25.4, 34.6 and 35.3±0.1° 2θ.
15 . The method according to claim 13 , wherein the pharmaceutical composition comprises no more than 40 wt % of the triethylenetetramine tetrahydrochloride Form A having an XRPD pattern having peaks at 25.2 and 35.7±0.1° 2θ.
16 . The method according to claim 13 , wherein the pharmaceutical composition comprises no more than 20 wt % of triethylenetetramine tetrahydrochloride Form A having an XRPD pattern having peaks at 25.2 and 35.7±0.1° 2θ.
17 . The method according to claim 13 , wherein the pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent.
18 . The method according to claim 13 , wherein the pharmaceutical composition is a solid oral dosage form.
19 . The method according to claim 18 , wherein the solid oral dosage form comprises a tablet, capsule or powder.
20 . The method according to claim 19 , wherein the solid oral dosage form is a tablet.
21 . Method according to claim 13 , wherein the pharmaceutical composition comprises no more than 10 wt % triethylenetetramine tetrahydrochloride Form A having an XRPD pattern having peaks at 25.2 and 35.7±0.1° 2θ.
22 . The method according to claim 13 , wherein the pharmaceutical composition comprises no more than 5 wt % triethylenetetramine tetrahydrochloride Form A having an XRPD pattern having peaks at 25.2 and 35.7±0.1° 2θ.
23 . The method according to claim 13 , wherein the subject is a mammal.
24 . The method according to claim 23 , wherein the mammal is a human.